Search

Displaying results 1811 - 1820 of 10000 in total
  1. Drug

    Enfuvirtide

    go.drugbank.com/drugs/DB00109
    ApprovedInvestigational

    Enfuvirtide is a 36 amino acid biomimetic peptide that is structurally similar to the HIV proteins that are responsible for the fusion of the virus to cell membranes and subsequent intracellular uptake … The first agent in the novel class of antiretroviral drugs called HIV fusion inhibitors, enfuvirtide works by inhibiting HIV-1 fusion with CD4 cells.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2E1 SubstratesProducts: FUZEON POLVO SOLUCION INYECTABLE 90 MG/MI
  2. Drug

    Isoniazid

    go.drugbank.com/drugs/DB00951
    ApprovedInvestigational

    Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.

    Mixtures: DOTBAL-S, RINCURE ® 3 FDC TABLETAS CON PELICULACategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inhibitors
  3. Drug

    Fosdenopterin

    go.drugbank.com/drugs/DB16628
    Approved

    (cPMP) - is interrupted. … [A230088] MoCD is incurable and median survival in untreated patients is approximately 36 months[A230088] - treatment, then, is focused on improving survival and maintaining neurological function.

    Synonyms: C(PMP)Categories: MATE 1 Substrates, MATE 2 Inhibitors
  4. Drug

    Strontium ranelate

    go.drugbank.com/drugs/DB09267
    ApprovedWithdrawn

    Strontium ranelate, a strontium (II) salt of ranelic acid, is a medication for osteoporosis. … It is therefore promoted as a "dual action bone agent" (DABA) indicated for use in treatment of severe osteoporosis.

    Mixtures: FULLBONE D3 2 G/800 IU EFERVESAN TABLET, 30 ADET, FULLBONE D3 2 G/800 IU EFERVESAN TABLET, 60 ADETCategories: Heterocyclic Compounds, 1-Ring
  5. Drug

    Propylthiouracil

    go.drugbank.com/drugs/DB00550
    Approved

    It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534) … A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine.

    Synonyms: 2-Mercapto-6-propyl-4-pyrimidone, 2-Mercapto-6-propylpyrimid-4-oneCategories: Heterocyclic Compounds, 1-Ring
  6. Drug

    Apremilast

    go.drugbank.com/drugs/DB05676
    ApprovedInvestigational

    Apremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. … [A181244,L7495] Initially approved in 2014, it is marketed by Celgene.

    Mixtures: OTEZLA 10 MG. 20 MG Y 30 MG, OTEZLA 10 MG. 20 MG Y 30 MGCategories: Cytochrome P-450 Substrates, P-glycoprotein substrates
  7. Drug

    Dotatate gallium Ga-68

    go.drugbank.com/drugs/DB13925
    ApprovedInvestigationalWithdrawn

    Dotatate gallium (Ga-68) is a somatostatin-2 receptor analog which is radiolabeled with gallium 68 as a positron-emitting radioisotope. … Ga-68 dotatate has a high affinity for somatostatin-2 receptor and it is rapidly excreted from the nontarget sites which gives it an ideal candidate for imaging neuroendocrine tumors.

  8. Drug

    DaxibotulinumtoxinA

    go.drugbank.com/drugs/DB17929
    ApprovedInvestigational

    It is a botulinum toxin without accessory proteins purified from the bacterium _Clostridium botulinum_ type A,[L47840] the gram-positive anaerobic bacterium primarily present in soil. … _C. botulinum_ is known to produce toxins that can cause botulism in humans.

    Categories: Botulinum Toxins, Type A
  9. Drug

    Elagolix

    go.drugbank.com/drugs/DB11979
    ApprovedInvestigational

    Moreover, women who are affected by this condition can suffer for up to six to ten years and visit multiple physicians before receiving a proper diagnosis [A35868, A35869, F801]. … It has been determined that endometriosis is one of the most common gynecologic disorders in the United States [A35868, A35869, F801].

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  10. Drug

    Samidorphan

    go.drugbank.com/drugs/DB12543
    ApprovedInvestigational

    [A235638, A235643] Samidorphan is a novel opioid antagonist structurally related to [naltrexone], with a higher affinity for opioid receptors, more potent μ-opioid receptor antagonism, higher oral bioavailability … [A235638, A235643] Samidorphan was first approved as a variety of fixed-dose combination tablets with [olanzapine] by the FDA on May 28, 2021, and is currently marketed under the trademark LYBALVI™

    Salts: Samidorphan L-malateCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates